Pagibaximab

Pagibaximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	staphylococcal lipoteichoic acid
Clinical data
ATC code	none;
Identifiers
CAS Number	595566-61-3 ;
ChemSpider	none;
Chemical and physical data
Formula	C6462H9996N1728O2028S54
Molar mass	146,072.36 g·mol−1
(what is this?) (verify)

Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010^[update], it is undergoing Phase II/III clinical trials.^[1]^[2]

References[edit]

^ Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. PMC 2704668 . PMID 19380597. doi:10.1128/AAC.01565-08.
^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.